Titration News and Research

RSS

Presentation of results from open-label extension study of Xenazine

Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p< 0.0001) as measured using the Unified Huntington's Disease Rating Scale (UHDRS) compared with baseline.

6 Mar 2010

Study confirms efficacy and tolerability of lacosamide for uncontrolled POS

A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients.

26 Feb 2010

Breakthrough discovery could help in developing a broad spectrum of antiviral drugs

Within a virus's tiny exterior is a store of energy waiting to be unleashed. When the virus encounters a host cell, this pent-up energy is released, propelling the viral DNA into the cell and turning it into a virus factory.

6 Feb 2010

Positive results from Supernus Pharmaceuticals' SPN 810 Phase IIa trial for ADHD

Supernus Pharmaceuticals Inc., today announced that its Phase IIa U.S. clinical trial for SPN 810 in children with ADHD and persistent serious conduct problems met the primary endpoints of safety and tolerability, as well as showed statistically significant reduction versus baseline in conduct problems across all doses. The trial was initiated in 2009 and was a proof-of-concept, open-label study in children 6 to 12 years of age, assigned to one of four doses over a six-week treatment period, after 2-5 weeks' titration.

27 Jan 2010

Researchers develop new technique for pH adjustments

How do individual cells or proteins react to changing pH levels? Researchers at the MESA+ Institute for Nanotechnology at the University of Twente have developed a technique for 'gently' adjusting pH: in other words, without damaging biomolecules. This should soon allow them to measure the activity of a single enzyme as a function of pH.

22 Dec 2009

FDA approves two New Drug Applications

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced that the US Food and Drug Administration (FDA) has approved its first two New Drug Applications (NDAs) based on its proprietary OralXR+(TM) platform technology including the first-ever 24 hour liquid sustained release product.

7 Dec 2009

ImThera Medical implants its aura6000 neurostimulation device in two OSA patients

ImThera Medical, Inc. today announced that two patients have been surgically implanted with ImThera’s aura6000™ neurostimulation device for treating tongue-based Obstructive Sleep Apnea (OSA). Patients are being enrolled in ImThera’s pilot clinical investigation in Belgium with the first results expected to be published in the first half of 2010.

2 Dec 2009

70% of 350 US physicians will increase the use niacin for patients, says report

Sermo (http://www.sermo.com), the world's largest online physician's community, today announced the results of a new report indicating that 70% of 350 US physician respondents would increase their use of niacin based on results from the ARBITER 6-HALTS trial.

2 Dec 2009

Contour Products promotes the results of a 2009 survey conducted among respiratory therapists

In conjunction with National Respiratory Care Week, Contour Products(TM), a leader in the sleep support and comfort industry, is proud to promote the results of a 2009 survey conducted among respiratory therapists who work with CPAP patients daily. One of the most common issues among CPAP therapy users is discomfort when sleeping with their CPAP mask, as a result of the mask pressing against their face.

28 Oct 2009

Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave

Orexigen® ( )Therapeutics, Inc today announced new data from the COR-I, COR-II and COR-Diabetes trials for Contrave® (bupropion SR/ naltrexone SR) to expand on top-line results announced in July. Contrave is the first of the Company's two late stage candidates for the treatment of obesity.

26 Oct 2009

Aspect Medical Systems to present a complete family of BIS monitoring technologies at ASA meeting

The American Society of Anesthesiologists (ASA) Annual Meeting will feature 62 scientific presentations that reference BIS® monitoring when it convenes on October 17-21, 2009 in New Orleans. BIS-related research will cover a broad range of applications for BIS monitoring, including initial results from studies conducted as part of a comparative effectiveness research collaboration with the Cleveland Clinic as well as findings from a study evaluating use of a Composite Variability Index (CVI) that is based on BIS parameters.

20 Oct 2009

Holistic care needed for people with Alzheimer's disease and dementia

Whilst cognitive function can be improved by the medicines currently available for the treatment of dementias, the positive effects of improved socialibility, initiative and motivation on the patient and their carer as well as their capability of coping with everyday life should not be overlooked says a research report published by the Pharmacy Practice Research Trust (the Trust).

12 Oct 2009

AVI BioPharma receives $11.5M DTRA fund to develop AVI-7012 for treating Junin virus infection

AVI BioPharma, Inc. a developer of RNA-based drugs, announced today that it has received expanded contract funding of approximately $11.5 million from the Defense Threat Reduction Agency's (DTRA) Transformational Medical Technologies Initiative (TMTI) to support development of the Investigational New Drug (IND) data package for its candidate drug, AVI-7012, to treat Junin virus infection.

5 Oct 2009

Clinical study results demonstrate the efficacy of AFRESA inhalation powder

AFRESA (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, showed no significant changes in pulmonary function and sustained glycemic control in adult patients with type 2 diabetes over four years of continuous treatment, according to data presented today at the 45th Annual Meeting of the European Association for the Study of Diabetes.

2 Oct 2009

Results from the BLOSSOM trial announced by Arena Pharmaceuticals

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported today positive, highly significant top-line results from the BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) trial.

18 Sep 2009

Phase III clinical trial results of DAR-31 published

Gilead Sciences, Inc. today announced the publication of data from DAR-311 (DORADO), a Phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, defined as the failure to achieve blood pressure goal while adhering to full doses of an appropriate three (or more) drug antihypertensive regimen that includes a diuretic.

14 Sep 2009

The Kyoto Heart study shows positive effect of valsartan on cardiovascular outcome

The KYOTO HEART Study, which took place in Japan between January 2004 and January 2009, shows that the addition of valsartan to conventional antihypertensive treatment to improve blood pressure control is associated with an improved cardiovascular outcome in Japanese hypertensive patients at high risk of CVD events.

2 Sep 2009

Study reveals that valsartan prevents cardiovascular events in high-risk hypertensive Japanese patients

2 Sep 2009

FDA approves Extavia for multiple sclerosis

The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.

17 Aug 2009

Low-income patients with obstructive sleep apnea are less likely to start CPAP therapy

A study in the April 1 issue of the journal SLEEP demonstrates that low socioeconomic status independently predicts the poor acceptance of continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea, and patients with higher incomes are more likely to begin treatment.

1 Apr 2009